+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of a coated-tube assay for antithyrotropin receptor antibodies in patients with Graves' disease and other thyroid disorders



Evaluation of a coated-tube assay for antithyrotropin receptor antibodies in patients with Graves' disease and other thyroid disorders



Thyroid 14(4): 295-300



The detection of autoantibodies to the thyrotropin-receptor antibody (TRAb) is commonly used in clinical practice for the diagnostic assessment of Graves' disease (GD) and its differential diagnosis from toxic multinodular goiter (MNG) and autonomous adenoma. Additionally, TRAb assays can be useful during antithyroid drug treatment of GD to evaluate the risk of relapse and/or remission. The detection of TRAb was originally performed using a radioreceptor assay based on detergent-solubilized porcine thyroid membranes (TRAb). More recently new assays using purified porcine or recombinant human thyrotropin (TSH) receptor-coated plastic tubes (CT) have been developed (pCT-TRAb or hCT-TRAb). We have evaluated both assays (TRAb and pCTTRAb) in 300 individuals: healthy controls (n = 51); patients with GD before and after treatment (n = 200), patients with MNG (n = 29), and Hashimoto's thyroiditis [HT; n = 20]). All healthy controls and patients with HT had undetectable TRAb using both methods. Patients with active (not treated) GD had higher pCT-TRAb values (mean +/- standard deviation [SD], 58.2% +/- 20.3%, inhibition of TSH binding) compared to TRAb (41.2% +/- 15.4%, p < 0.01, Wilcoxon test). Results (as percent inhibition for both methods) had a positive and significant correlation (r = 0.68, p < 0.001). Moreover TRAb assay had a 97.3% sensitivity and 96.8% specificity; the pCT-TRAb sensitivity was 96.3% and specificity was 98.4% at a cutoff of 1.51 U/L. During treatment of GD, the TRAb method resulted in significantly lower (p < 0.05) values at 12, 24, and 30 months, while pCT-TRAb only exhibited significancy (compared to basal levels) at 30 months. The percent inhibition after 131I treatment of GD was significantly higher for pCT-TRAb (33.7 +/- 25.7) compared to TRAb (21.9 +/- 17.7, p < 0.01, Wilcoxon test). Only one patient with untreated MNG had a positive pCT-TRAb but negative TRAb value. Patients with MNG treated with 131I were divided into two groups: group 1 (only (131)I) or group 2 (hrTSH preceding (131)I). After MNG radioisotopic ablation, five patients had a positive pCT-TRAb and four had a positive TRAb (group 1) while in group 2, three patients had a positive pCT-TRAb and two had a positive TRAb assay. In conclusion, pCT-TRAb usually had higher percent inhibition values compared to TRAb in untreated GD, had a relatively lower decrease in percent inhibition values during treatment but exhibited a slightly increased sensitivity compared to TRAb. An advantage of the pCT-TRAb assay may be because of the coating system itself that might expose more receptor sites for the antibody.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048993292

Download citation: RISBibTeXText

PMID: 15142363

DOI: 10.1089/105072504323030951


Related references

Variable regions of Ig heavy chain genes encoding antithyrotropin receptor antibodies of patients with Graves' disease. Journal of Immunology 152(3): 1485-1492, 1994

Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease. International Journal of Clinical Pharmacology Research 24(4): 111-116, 2004

Antithyrotropin antibodies in the sera of Graves' disease patients. Journal of Clinical Endocrinology and Metabolism 61(2): 217-222, 1985

Binding of antithyrotropin receptor autoantibodies in Graves' disease serum to nascent, in vitro translated thyrotropin receptor: ability to map epitopes recognized by antibodies. Journal of Clinical Endocrinology and Metabolism 81(2): 700-706, 1996

Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves' disease: epitope and binding study of two stimulatory TSHRAbs. Endocrinology 140(4): 1594-1601, 1999

A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease. Clinical Endocrinology 64(4): 429-435, 2006

Thyroid stimulating hormone receptor antibodies hla b 8 and thyroid auto antibodies in patients with graves disease in therapeutically induced eu thyroidism. Experientia (basel): 1408-1409, 1979

Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow. Thyroid 24(6): 1027-1031, 2014

Significance of circulating anti thyroid stimulating hormone tsh receptor antibodies in patients with autoimmune thyroid diseases thyroid stimulation blocking antibody in patients with graves' disease. Journal of UOEH 11(4): 393-402, 1989

Clinical studies on abnormal thyroid stimulators in patients with graves' disease i. a sensitive assay for thyroid stimulating antibodies using cultured porcine thyroid cells and polyethylene glycol precipitation of serum. Folia Endocrinologica Japonica 64(3): 193-205, 1988

A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid 20(8): 851-856, 2010

Clinical applications of the 2nd generation assay for anti-TSH receptor antibodies in Graves' disease. Evaluation in patients with negative 1st generation test. Clinical Chemistry and Laboratory Medicine 39(1): 25-28, 2001

Hashimoto's thyroiditis with heterogeneous antithyrotropin receptor antibodies: unique epitopes may contribute to the regulation of thyroid function by the antibodies. Journal of Clinical Endocrinology and Metabolism 85(6): 2116-2121, 2000

Measurement of thyrotropin receptor antibodies (TRAK) with a second generation assay in patients with Graves' disease. Nuklearmedizin. Nuclear Medicine 39(4): 113-120, 2000

TSH-receptor antibodies, HLA B8 and thyroid autoantibodies in patients with Graves' disease in therapeutically induced euthyroidism. Experientia 35(10): 1408-1409, 1979